

A<sup>3</sup> 39. A pharmaceutical composition, comprising: a therapeutically effective amount of at least one compound as claimed in claim 1 and one or more pharmaceutically acceptable carriers, diluents or excipients.


A<sup>4</sup> 40. A method of treating a human or animal subject suffering from a disorder mediated by aberrant protein kinase activity, comprising administering to said mammal a therapeutically effective amount of at least one compound as claimed in claim 1.

Please cancel claims 44-48.

**REMARKS**

Currently claims 1-48 are pending. Claims 44-48 are cancelled. The claims 36, 39, and 40 have been amended to reduce the filing fee by removing multiple dependency. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,

  
John L. Lemanowicz  
Attorney for Applicants  
Registration No. 38,370

Date: 1/9/2002  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Phone: 919-483-8247  
Facsimile: 919-483-7988

10030527 "010902

**ABSTRACT**


**Anilinoquinazolines as Protein Tyrosine Kinase Inhibitors**

Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

10030527 010902

Marked-Up Copy of Amended Claims

37. A compound of [any one of] claim[s] 1 [to 35], wherein the compound is a compound of formula (I')



39. A pharmaceutical composition, comprising: a therapeutically effective amount of at least one compound as claimed in claim[s] 1 [to 38] and one or more pharmaceutically acceptable carriers, diluents or excipients.

40. A method of treating a human or animal subject suffering from a disorder mediated by aberrant protein kinase activity, comprising administering to said mammal a therapeutically effective amount of at least one compound as claimed in claim[s] 1 [to 38].

10030527 010902